Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product DevelopmentRecent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in AustraliaOptimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in AustraliaUpdated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA
